VRDN News
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1...
Business Wire
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1...
Business Wire
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +19.80% and +348.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30...
Business Wire
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of -2.50% and -98.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on...
Business Wire
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual...
Business Wire
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30...
Business Wire
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Zacks
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.read more...
Benzinga